Sparsentan is an investigational therapeutic candidate for the treatment of IgA nephropathy
Sparsentan, a Dual Endothelin Angiotensin Receptor Antagonist (DEARA), is a novel investigational product candidate in Phase 3 development for the treatment of IgA nephropathy (IgAN). IgA nephropathy, also called Berger’s disease, is a rare kidney disorder characterized by the buildup of immunoglobulin A (IgA), a protein that helps the body fight infections, in the kidneys. The deposits of IgA cause a breakdown of the normal filtering mechanisms in the kidney, leading to blood in the urine (hematuria), and protein in the urine (proteinuria). Other symptoms of IgA nephropathy may include kidney pain, swelling (edema) and high blood pressure. Over time, IgA nephropathy can progress to end-stage kidney disease (ESKD). The US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have granted sparsentan orphan drug designation for IgA nephropathy.